Thermo Fisher Scientific is proud to announce the successful conclusion of its highly anticipated Bioprocess World Tour 2024 in the Asia-Pacific and Japan (APJ) region, marking the return of this flagship event after a hiatus due to COVID-19. Held across key markets in South Korea, Japan, and India, the tour brought together leading bioprocessing experts and industry stakeholders to explore the latest advancements in antibody manufacturing, with a particular focus on productivity and efficiency.

The theme of this year's event revolved around addressing traditional monoclonal antibody (mAb) challenges and the evolution of next-generation antibodies. Through insightful presentations and discussions, participants had the opportunity to deep dive into innovations designed to drive efficiencies and improve outcomes in antibody production, a critical area of focus for the biopharmaceutical industry.

"Our goal at Thermo Fisher is to always stay ahead of what's next in bioprocessing and to continuously add value for our customers," said spokesperson at event site, Thermo Fisher Scientific. "This event was a fantastic platform to not only strengthen our market presence but also to forge stronger relationships with our customers. We're extremely grateful to our dedicated country teams, whose collective efforts made this event a success."

A special thank you goes out to all the speakers, participants, and organizers who contributed to the success of this year's tour. The event emphasized Thermo Fisher's commitment to innovation, collaboration, and supporting the biopharmaceutical industry's evolving needs.

Thermo Fisher looks forward to continued collaboration and partnership as the company remains focused on delivering cutting-edge solutions that help its customers bring life-saving therapies to market faster and more efficiently.